A Genetic Substudy Associated With the Avastin (Bevacizumab) Study MO19390 in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer.
Local Substudy Associated to the International Study MO19390 to Determine the BRCA1 Gene mRNA Expression as a Predictive Marker of Response to Chemotherapy
Sponsor: Hoffmann-La Roche
Terminated
Terminated due to low enrollment. No statistical analyses were performed.
Other terminated trials from Hoffmann-La Roche
Listed as NCT00642824, this PHASE2 trial focuses on Non-Squamous Non-Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by Hoffmann-La Roche, it has been updated 6 times since 2007, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
May 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hoffmann-La Roche
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcorcón, Spain , Alcoy, Spain , Alicante, Spain , Badalona, Spain , Barakaldo, Spain , Burgos, Spain , Elche, Spain , Girona, Spain , Huesca, Spain , Las Palmas de Gran Canaria, Spain and 9 more locations